

CLAIMS:

1. Peptide having 13-55 amino acid residues characterized in that said peptide comprises the amino acid sequence

A G W L R<sub>1</sub> D R<sub>2</sub> R<sub>3</sub> R<sub>4</sub> R<sub>5</sub> Y P I

in which R<sub>1</sub> = A, S

R<sub>2</sub> = Q, R, G

R<sub>3</sub> = T, S

R<sub>4</sub> = V, L

R<sub>5</sub> = R, Q.

with the provision that the peptide is not SSAGWLADRSVRYPIISKARPNXGG,  
NAGWLSGDSVQYPITKPREP, DAGWLADGHSVRYPIISRPRKR,  
GGLDWCNAGWLSGDSVQYPITKPR or  
EQLFAAYEDGFECQDAGWLADQTVRYPIRAPRVGCY.

2. Peptide having 13-55 amino acid residues characterized in that said peptide comprises at least the amino acid sequence

A G W L R<sub>1</sub> D R<sub>2</sub> R<sub>3</sub> L R<sub>5</sub> Y P I

in which R<sub>1</sub> = A, S

R<sub>2</sub> = Q, R, G

R<sub>3</sub> = T, S

R<sub>5</sub> = R, Q.

3. Peptide having 13-55 amino acid residues characterized in that said peptide comprises at least one of the amino acid sequences AGWLADQTVRYPI,  
AGWLADRSVRYPI, AGWLSGDSVQYPI and AGWLADGSLRYPI.

15  
18

4. Peptide consisting of one of the amino acid sequences AGWLADQTVRYPI, AGWLADRSVRYPI, AGWLSDGSVQYPI and AGWLADGSLRYPI.
5. Peptide having 13-55 amino acid residues and comprizing the amino acid sequence A G W L R<sub>1</sub> D R<sub>2</sub> R<sub>3</sub> R<sub>4</sub> R<sub>5</sub> Y P I in which R<sub>1</sub> = A, S, R<sub>2</sub> = Q, R, G, R<sub>3</sub> = T, S, R<sub>4</sub> = V, L, and R<sub>5</sub> = R, Q, for use as a medicament.
6. Pharmaceutical preparation comprizing a peptide having 13-55 amino acid residues, said peptide comprizing the amino acid sequence A G W L R<sub>1</sub> D R<sub>2</sub> R<sub>3</sub> R<sub>4</sub> R<sub>5</sub> Y P I in which R<sub>1</sub> = A, S, R<sub>2</sub> = Q, R, G, R<sub>3</sub> = T, S, R<sub>4</sub> = V, L, and R<sub>5</sub> = R, Q, and a pharmaceutical acceptable carrier.
7. Pharmaceutical preparation comprizing a peptide having 13-55 amino acid residues, said peptide comprizing the amino acid sequence A G W L R<sub>1</sub> D R<sub>2</sub> R<sub>3</sub> L R<sub>5</sub> Y P I in which R<sub>1</sub> = A, S, R<sub>2</sub> = Q, R, G, R<sub>3</sub> = T, S and R<sub>5</sub> = R, Q, and a pharmaceutical acceptable carrier.
8. Pharmaceutical preparation comprizing a peptide having 13-55 amino acid residues, said peptide comprizing at least one of the amino acid sequences AGWLADQTVRYPI, AGWLADRSVRYPI, AGWLSDGSVQYPI and AGWLADGSLRYPI.
9. Pharmaceutical preparation comprizing at least one of the peptides AGWLADQTVRYPI, AGWLADRSVRYPI, AGWLADGSLRYPI and AGWLSDGSVQYPI and a pharmaceutical acceptable carrier.
10. Use of a peptide having 13-55 amino acid residues, said peptide comprizing the amino acid sequence A G W L R<sub>1</sub> D R<sub>2</sub> R<sub>3</sub> R<sub>4</sub> R<sub>5</sub> Y P I in which R<sub>1</sub> = A, S, R<sub>2</sub> = Q, R, G, R<sub>3</sub> = T, S, R<sub>4</sub> = V, L, and R<sub>5</sub> = R, Q, for the manufacture of a pharmaceutical preparation for use in a peptide-induced tolerance therapy for the induction of tolerance to autoaggressive T cells associated with T-cell mediated articular cartilage destruction in autoimmune diseases.

add  
a/